Amgen and the Amgen Foundation Commit $12.5 Million to Support Global COVID-19 Response

THOUSAND OAKS, Calif., April 1, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and the Amgen Foundation announced an initial commitment of $12.5 million to support global efforts against the novel coronavirus (COVID-19) and aid communities affected by the pandemic. The funding will support Amgen’s emergency response initiatives in communities worldwide, pandemic prevention and control projects undertaken by patient organizations, as well as international relief efforts by Direct Relief and International Medical Corps. Additionally, the Amgen Foundation will match donations made by Amgen employees globally.

“The COVID-19 pandemic has presented a series of unprecedented challenges to people worldwide, governments, and healthcare systems. Currently, there is an urgent need for communities to take effective measures to slow the spread of the virus and support those directly affected by the outbreak,” said Robert A. Bradway, Chairman and Chief Executive Officer of Amgen. “As community needs become clearer, we hope this initiative will provide critical support to the front lines and help relevant organizations join forces in the fight against the pandemic.”

In addition, the “Amgen Foundation-supported”LabXchange™" and "Khan Academy Online Learning Website“Online science learning platforms will be made freely accessible to help students continue their science education while schools are closed. LabXchange, a free online science education platform developed by the Faculty of Arts and Sciences at Harvard University, offers users personalized instruction, virtual laboratory experiences, and opportunities for online engagement with the global scientific community. To date, with support from the Amgen Foundation, the Khan Academy platform has provided more than 300 videos, 80 practice sets, and 195 articles in biology-related courses.”

About the Amgen Foundation

The Amgen Foundation is dedicated to advancing science education, inspiring innovation in the next generation, and strengthening the communities where Amgen employees live and work. To date, the Foundation has donated nearly $325 million to local, regional, and national nonprofit organizations, giving back to society in innovative ways. Amgen inspires and cultivates future scientists through several science education programs, including the Amgen Scholars and the Amgen Biotech Experience. For more information, please visitAmgenInspires.comand follow the Twitter account@AmgenFoundation。

About Amgen

Amgen is dedicated to benefiting patients worldwide suffering from serious diseases by unlocking the potential of biology. To realize this vision, Amgen has long focused on the discovery, research and development, manufacturing, and marketing of innovative human therapeutics, leveraging cutting-edge tools such as human genetics to unravel the complexity of diseases and gain insights into the fundamental mechanisms of human biology.

Amgen focuses on disease areas with significant and largely unmet medical needs, leveraging its advanced expertise in biopharmaceuticals to make outstanding contributions to improving human health and quality of life. Since its founding in 1980, Amgen has become one of the world’s leading independent biotechnology companies, providing innovative medicines to millions of patients worldwide while maintaining a robust pipeline of highly promising investigational drugs.

For more information, please visitwww.amgen.comand followwww.twitter.com/amgen。

About Amgen China

Since entering China in 2012, Amgen has remained committed to its mission of serving patients, leveraging science and biotechnology to benefit Chinese patients and improve public health. Headquartered in Shanghai, Amgen’s business operations span nearly 80 cities across China. In the country, Amgen focuses on chronic disease areas with significant unmet needs, such as cardiovascular diseases and bone health, providing patients with innovative and superior treatment options.

Upholding the mission of scientific leadership and the pursuit of excellence, Amgen established its Asia Research and Development Center in Shanghai in 2014. Guided by the principle of “Biology First,” the Amgen Asia R&D Center is dedicated to translating the potential of science and biotechnology into innovative therapies that save lives and improve health.

For more information, please visitwww.amgen.cn。